Text Size

Proper Dosage of Ketamine in Intravenous Regional Anesthesia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by University Health Network, Toronto.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00221871
First received: September 20, 2005
Last updated: October 10, 2006
Last verified: September 2005
History of Changes
  Purpose

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.


Condition Intervention
Pain.
 Drug: Different dosages of Ketamine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Health Network, Toronto:

Study Start Date: January 2004
Estimated Study Completion Date: January 2005
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18-70
  2. Weight: 50-100 kg
  3. ASA: I, II, III
  4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

  1. Contraindication to IVRA such as sickle cell disease.
  2. Any known hypersensitivity reaction to Ketamine.
  3. History of chronic pain or regular medication with analgesics.
  4. History of opioid dependence.
  5. Drug of alcohol abuse.
  6. Psychiatric disorder.
  7. Allergy to acetaminophen or codeine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00221871

Contacts
Contact: Colin McCartney, MD (416)603-5118 colin.mccartney@uhn.on.ca

Locations
Canada, Ontario
University Health Network Recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Filomena Valle-Leutri, BSc     (416)603-5800 ext 2016     filomena.valle-leutri@uhn.on.ca    
Principal Investigator: Colin McCartney, MD            
Sub-Investigator: Vincent Chan, MD            
Sub-Investigator: Philip Peng, MD            
Sub-Investigator: Paul Tumber, MD            
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Colin McCartney, MD University Health Network, Toronto
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00221871     History of Changes
Other Study ID Numbers: UHN02-0233-A
Study First Received: September 20, 2005
Last Updated: October 10, 2006
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Anesthetics
Ketamine
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anesthetics, Dissociative
Anesthetics, Intravenous
 Anesthetics, General
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on May 16, 2013